Clinical Trial Update: Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II ) [Phase 3]

View source ↗

Summary

Completed Phase 3 trial (BRAINSAFE-II) evaluating hydroxyurea for neurological and cognitive protection in children with sickle cell disease in Uganda.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: Global Health Uganda LTD | Conditions: Sickle Cell Anemia in Children | Phase 3 | Status: COMPLETED